# OnCo record pd-l1-testing (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/pd-l1-testing/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "pd-l1-testing" ;
  schema:name "PD-L1 expression testing (22C3, SP142, SP263)"@en ;
  schema:alternateName "PD-L1 expression"@en, "PD-L1-positive"@en, "PD-L1 positive"@en, "PD-L1-negative"@en, "PD-L1 negative"@en, "PD-L1-high"@en, "PD-L1 high"@en, "PD-L1-low"@en, "PD-L1 status"@en, "PD-L1 IHC"@en, "22C3"@en, "SP142"@en, "SP263"@en, "28-8"@en, "PD-L1 ≥50%"@en, "PD-L1 ≥1%"@en ;
  schema:description "A stain on the tumour biopsy that measures how much of the PD-L1 'don't attack me' protein is present, scored as a tumour proportion or combined positive score. Higher levels usually mean checkpoint inhibitors work better, and approvals in lung, triple-negative breast, gastric and head and neck cancer set minimum scores; yet PD-L1-negative tumours sometimes respond."@en ;
  schema:url <https://onco.cc/terms/pd-l1-testing/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/PD-L1> ;
  schema:citation <https://en.wikipedia.org/wiki/PD-L1> ;
  onco:related <https://onco.cc/terms/cps/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/immuno-oncology/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/pdl1/> .